candidate population for glp agonists - SERP Analysis

https://www.westlakedermatology.com/blog/ideal-candidates-glp-1-weight-loss/

https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

https://visiblealpha.com/blog/visible-alpha-glp-1-drug-monitor-blockbusters-up-and-comers/

https://pmc.ncbi.nlm.nih.gov/articles/PMC7042958/

https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

https://www.sciencedirect.com/science/article/pii/S1544319123003096

https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists

https://www.globenewswire.com/news-release/2025/03/18/3044263/28124/en/GLP-1-Market-Industry-Trends-and-Global-Forecasts-2024-2035-Over-150-GLP-1-Drug-Candidates-in-Development-for-Multiple-Indications-Type-2-Diabetes-and-Obesity-Drive-GLP-1-Drug-Deve.html

https://www.healthline.com/health/type-2-diabetes/considering-glp1s

https://pmc.ncbi.nlm.nih.gov/articles/PMC7744318/

https://kochresearch.com/blogs/who-is-a-good-candidate-for-glp-1

https://www.ohe.org/insights/glp-1-receptor-agonists-shifting-obesity-management/

https://www.jhltonline.org/article/S1053-2498(24)01061-1/fulltext

https://www.hopkinsmd.com/blog/qualifying-for-glp-1-weight-loss-whos-a-good-candidate

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00340-0/fulltext

https://isyaderm.com/who-is-a-candidate-for-mounjaro-glp1-treatment/

https://medicine.yale.edu/media-player/glp-1-agonists-wonder-drugs-of-the-21st-century/

https://www.nature.com/articles/s41392-024-01931-z

https://keystonehealth.org/blog/glp-1-agonists-in-obesity/

https://www.sciencedirect.com/science/article/pii/S2667368124000299

https://visiblealpha.com/blog/visible-alpha-glp-1-drug-monitor-the-emerging-pipeline/

https://www.biospace.com/drug-development/7-indications-for-glp-1s-beyond-weight-loss

https://www.bmj.com/content/384/bmj-2023-076410

https://www.everydayhealth.com/diabetes/why-minorities-are-less-likely-to-be-prescribed-glp-1s/

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.113.006985

https://www.kidney.org/kidney-topics/glp-1-receptor-agonists-glp-1-ras

https://nhmwellness.com/who-is-a-good-candidate-for-glp-1/

https://www.aaas.org/news/innovators-glp-1-obesity-bhaumik-breakthrough

https://www.mdpi.com/2077-0383/12/1/145

https://www.integrativehealthnwi.com/who-is-a-good-candidate-for-glp-1-weight-loss-medications/

https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.721135/full

https://joinfound.com/blog/shopping-for-glp-1-prescriptions-for-weight-loss-heres-what-responsible-prescribing-looks-like?srsltid=AfmBOooybMTgt11gnWR3yFdNw38Kl_lNqPV9JlfCjqgrnbt2QLrQsfGf

https://moshp.org/news/694319/Safety-and-Efficacy-of-GLP-1-Receptor-Agonists-in-Post-transplant-Diabetes-Mellitus.htm

https://www.micariaesthetics.com/post/weight-loss-support-am-i-a-good-candidate-for-semaglutide/

https://diabetesjournals.org/clinical/article/38/4/390/35426/Switching-Between-Glucagon-Like-Peptide-1-Receptor

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development

https://www.krcp-ksn.org/upload/pdf/j-krcp-22-001.pdf

https://www.ama-assn.org/delivering-care/public-health/age-glp-1-agonists-food-choices-still-matter-health

https://www.youtube.com/watch?v=5MdEWprAxE0

https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.16541

https://www.apsf.org/article/are-serious-anesthesia-risks-of-semaglutide-and-other-glp-1-agonists-under-recognized/

https://www.healthline.com/health/weight-loss/glp1-for-weight-loss

https://www.news-medical.net/news/20250120/Researchers-create-an-atlas-of-health-associations-for-GLP-1-receptor-agonists.aspx

https://pro.novonordisk.com/disease-area/diabetes/understanding-glp1/glp-1-shift/glp-1-ra-education.html

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-advances-development-once-daily-formulation-oral-glp

https://www.fiercebiotech.com/biotech/zealand-pharmas-glp-1glp-2-candidate-linked-116-weight-loss-after-28-weeks

https://agelessrx.com/comparing-glp1-agonists-to-longevity-canditates/?srsltid=AfmBOoqzcw1F-vZtaQN8ypo6UortwXgmAOssRmlpjUCSjHfO_k7ozjkK

https://www.bjd-abcd.com/index.php/bjd/article/view/68/148

https://www.merck.com/news/merck-to-present-data-for-efinopegdutide-mk-6024-an-investigational-glp-1-glucagon-receptor-co-agonist-in-patients-with-nonalcoholic-fatty-liver-disease-nafld-at-easl-2023/

https://www.tandfonline.com/doi/full/10.1080/14796678.2024.2433381?src=exp-la

https://anad.org/glp-1-medications-eating-disorders/

https://www.nejm.org/doi/full/10.1056/NEJMoa2302392

https://www.bbrown.com/us/insight/weight-loss-drugs-glp-1-agonists/

https://www.cellr4.org/wp-content/uploads/sites/2/2020/12/e2943.pdf

https://www.healthcentral.com/condition/type-2-diabetes/type-2-diabetes-treatments-newer-medications

https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html

https://link.springer.com/article/10.1007/s00125-024-06099-3

https://www.science.org/content/blog-post/glp-1-and-obesity

https://www.medcentral.com/meds/which-glp-1-agonist-if-any-is-right-for-my-patient

https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market

https://www.reproductiveaccess.org/resource/possible-drug-interaction-between-glp-1-agonist-and-oral-contraceptives/

https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-research-treatment-diabetes-and-obesity

https://www.mdpi.com/2073-4409/13/1/65

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.067676?doi=10.1161/CIRCULATIONAHA.124.067676

https://www.biospace.com/glp-1-receptor-agonist-market-to-reach-125b-by-2033-globaldata

https://www.ozmosi.com/market-overview-glp-1-agonists-and-the-obesity-market/

https://www.lightrx.com/blog/who-is-a-good-candidate-for-glp1-weight-loss-therapy/

https://www.youtube.com/watch?v=gAssDThEPx8

https://www.everydayhealth.com/type-1-diabetes/surprising-potential-of-ozempic-for-type-1-diabetes/

https://www.thepharmaletter.com/pharmaceutical/positive-results-for-zealand-s-glp-1-glp-2-receptor-dual-agonist-dapiglutide

https://www.fiercebiotech.com/biotech/novo-nordisk-pens-2b-deal-triple-g-agonist-tied-15-weight-loss-12-weeks

https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730

https://www.researchgate.net/figure/The-GLP-1-Receptor-agonists-currently-on-the-market-or-in-clinical-development_tbl1_259488619

https://diabetesjournals.org/care/article/48/Supplement_1/S181/157569/9-Pharmacologic-Approaches-to-Glycemic-Treatment

https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf

https://www.seannikravanmd.com/blog/am-i-a-good-candidate-for-the-glp-1-weight-loss-medications

https://www.researchgate.net/figure/Effects-of-glucagon-like-peptide-1-GLP-1-receptor-stimulation-in-various-substance_fig2_354654042

https://www.jci.org/

https://www.amgen.com/newsroom/press-releases/2024/11/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52-weeks-in-a-phase-2-study

https://www.astrazeneca.com/our-therapy-areas/pipeline.html

https://consensus.app/

https://www.medicalnewstoday.com/articles/new-glp-1-agonist-potential-long-lasting-type-2-diabetes-treatment

https://www.pharmacytimes.com/view/ashp-midyear-expert-discusses-the-glp-1-landscape-for-diabetes-care

https://www.drugdiscoverytrends.com/glp-1-receptor-agonist-clinical-trials-semaglutide-leads/

https://www.businesswire.com/news/home/20250413297943/en/Pfizer-Provides-Update-on-Oral-GLP-1-Receptor-Agonist-Danuglipron

https://academic.oup.com/asj/article/44/4/NP279/7470696

https://www.pharmexec.com/view/2025-pharm-exec-top-50-companies

https://pharmaphorum.com/news/update-rumour-confirmed-lilly-buys-verve-therapeutics

https://insights.citeline.com/scrip/conferences/bio/bio-notebook-mfn-pricing-next-gen-obesity-rd-fdas-rare-disease-hub-reaction-to-review-program-SGIL3Y5LLBASBF6S6OVZL25H7M/

https://www.onlymyhealth.com/can-ozempic-lower-heart-attack-risks-expert-explains-12977832829

https://www.medicalnewstoday.com/articles/glp-1-receptor-agonists-type-2-diabetes

https://www.cnn.com/2024/05/21/health/glp-1-weight-loss-drugs-stop-treatment-real-world-effectiveness

https://medcitynews.com/2023/11/astrazeneca-glp1-obesity-cardiometabolic-eccogene/

https://finance.yahoo.com/quote/BMEA/

https://pipelinereview.com/biogen-initiates-phase-3-pediatric-study-of-omaveloxolone-for-the-treatment-of-friedreich-ataxia/

https://www.pharmacytimes.com/view/glp-1-gip-dual-agonist-tirzepatide-and-its-effect-on-current-weight-loss-therapy

https://insights.citeline.com/pink-sheet/conferences/bio/bio-notebook-mfn-pricing-obesity-rd-us-fdas-rare-disease-hub-and-reaction-to-review-program-VNEHA2M4TJFWDADF5MHGROO6MM/

https://www.healthcareinsights.md/

https://www.globenewswire.com/news-release/2025/06/18/3101731/0/en/Zealand-Pharma-announces-positive-topline-results-from-28-week-Phase-1b-trial-with-GLP-1-GLP-2-receptor-dual-agonist-dapiglutide.html